Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances

DSpace/Manakin Repository

Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances

Citable link to this page

 

 
Title: Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances
Author: Liu, Xiaochuan; Wang, Aoli; Liang, Xiaofei; Chen, Cheng; Liu, Juanjuan; Zhao, Zheng; Wu, Hong; Deng, Yuanxin; Wang, Li; Wang, Beilei; Wu, Jiaxin; Liu, Feiyang; Fernandes, Stacey M.; Adamia, Sophia; Stone, Richard M.; Galinsky, Ilene A.; Brown, Jennifer R.; Griffin, James D.; Zhang, Shanchun; Loh, Teckpeng; Zhang, Xin; Wang, Wenchao; Weisberg, Ellen L.; Liu, Jing; Liu, Qingsong

Note: Order does not necessarily reflect citation order of authors.

Citation: Liu, X., A. Wang, X. Liang, C. Chen, J. Liu, Z. Zhao, H. Wu, et al. 2016. “Characterization of selective and potent PI3Kδ inhibitor (PI3KD-IN-015) for B-Cell malignances.” Oncotarget 7 (22): 32641-32651. doi:10.18632/oncotarget.8702. http://dx.doi.org/10.18632/oncotarget.8702.
Full Text & Related Files:
Abstract: PI3Kδ is predominately expressed in leukocytes and has been found overexpressed in B-cell related malignances such as CLL and AML. We have discovered a highly selective ATP competitive PI3Kd inhibitor PI3KD-IN-015, which exhibits a high selectivity among other PI3K isoforms in both biochemical assays and cellular assay, meanwhile did not inhibit most of other protein kinases in the kinome. PI3KD-IN-015 demonstrates moderately anti-proliferation efficacies against a variety of B-cell related cancer cell lines through down-regulate the PI3K signaling significantly. It induced both apoptosis and autophagy in B-cell malignant cell lines. In addition, combination of autophagy inhibitor Bafilomycin could potentiate the moderate anti-proliferation effect of PI3KD-IN-015. PI3KD-IN-015 shows anti-proliferation efficacy against CLL and AML patient primary cells. Collectively, these results indicate that PI3KD-IN-015 may be useful drug candidate for further development of anti-B-cell related malignances therapies.
Published Version: doi:10.18632/oncotarget.8702
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078040/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:29408229
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters